No dividend, focussed on cardiac equipment like pacemakers. Have made many acqusitions in past years. Fabulous management. Have driven cost synergies consistently. Beat estimates recently. Forward earnings are 20x. A solid hold.

Fabulous stock. He took profits, but still likes this. Valuation has risen, currently at 27x earnings, which is why he exited.

Dialysis equipment amounts to 40% of their business. Sold his shares too early. They've had a great run. High 24x forward earnings. But the stock warrants a second look. Dividend just under 1% with negative growth and could
continue downward. Nine consecutive quarterly beats.

Long-term, this is the one to own. A dominant player in medtech and pharma. 10% of their revenue has been from one drug. Competition is weak. A well-run, large company. Valuations are okay. An anchor in his portfolio. Their diversified
portolio of drugs can withstand the failure of one.

CNQ-T versus SU-T. They both rank well in his model. In a rising interest rate world, energy stocks do well. CNQ ranks slightly higher as share earnings will grow 100% in 2018 with a 16 times P/E. He does not own either stock.

CNQ-T versus SU-T – They both rank well in his model. In a rising interest rate world, energy stocks do well. CNQ ranks slightly higher as share earnings will grow 100% in 2018 with a 16 times P/E. He does not own either stock.

He says the market was disappointed with recent earnings. This came from weaker gasoline margins in Europe and Arizona. It could be a sale for them at the end of the month, because of the 25% negative surprise on the earnings. Yield %.